PriceTargets.com logo

Aeglea BioTherapeutics - AGLE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.88
  • Forecasted Upside: 482.66%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.32 As of 03/23/2023 01:00 AM ET
▼ -0.01 (-3.01%)

This chart shows the closing price for AGLE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aeglea BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGLE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGLE

Analyst Price Target is $1.88
▲ +482.66% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aeglea BioTherapeutics in the last 3 months. The average price target is $1.88, with a high forecast of $3.00 and a low forecast of $1.00. The average price target represents a 482.66% upside from the last price of $0.32.

This chart shows the closing price for AGLE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Aeglea BioTherapeutics. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/3/2023HC WainwrightReiterated RatingNeutral$1.00Low
11/1/2022Piper SandlerBoost Target$1.50N/A
10/28/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$1.50 ➝ $2.00Low
10/27/2022Piper SandlerUpgradeNeutral ➝ OverweightLow
8/25/2022JonestradingReiterated RatingBuy$3.00Low
8/9/2022Wells Fargo & CompanyLower TargetEqual Weight$2.00 ➝ $1.50Low
6/2/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
6/2/2022HC WainwrightDowngradeBuy ➝ Neutral$17.00 ➝ $1.00High
6/2/2022Piper SandlerDowngradeOverweight ➝ Neutral$4.00 ➝ $1.00High
5/23/2022Piper SandlerLower TargetOverweight$7.00 ➝ $4.00Low
5/6/2022Piper SandlerLower Target$9.00 ➝ $7.00Low
5/5/2022HC WainwrightLower Target$20.00 ➝ $17.00Low
12/6/2021Piper SandlerLower TargetOverweight ➝ Overweight$12.00 ➝ $9.00High
11/5/2021Lifesci CapitalReiterated RatingOutperformLow
8/6/2021Evercore ISIInitiated CoverageBuy$20.00Medium
6/24/2021Needham & Company LLCReiterated RatingBuy$12.00High
11/9/2020HC WainwrightReiterated RatingBuy$17.00 ➝ $15.00High
10/23/2020Lifesci CapitalReiterated RatingOutperformMedium
9/16/2020HC WainwrightReiterated RatingBuy$17.00Medium
8/10/2020Needham & Company LLCReiterated RatingBuy$11.00High
5/26/2020Needham & Company LLCInitiated CoverageBuy$11.00Low
5/8/2020HC WainwrightLower TargetBuy$18.00 ➝ $17.00Low
5/7/2020Needham & Company LLCLower TargetBuy$14.00 ➝ $11.00High
5/4/2020Piper SandlerInitiated CoverageOverweight$12.00Medium
4/30/2020HC WainwrightLower TargetBuy$24.00 ➝ $18.00Low
4/8/2020Needham & Company LLCReiterated RatingBuy$14.00High
2/26/2020Needham & Company LLCReiterated RatingBuy ➝ Average$14.00High
2/25/2020HC WainwrightBoost TargetBuy$20.00 ➝ $24.00High
6/3/2019HC WainwrightReiterated RatingBuy$20.00Low
5/21/2019HC WainwrightInitiated CoverageBuy$20.00 ➝ $20.00High
3/21/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$14.00Medium
9/4/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
6/14/2018BMO Capital MarketsInitiated CoverageOutperform$21.00High
4/24/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$37.00High
4/13/2018Needham & Company LLCBoost TargetBuy$20.00High
(Data available from 3/23/2018 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/25/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/24/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/21/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/23/2023

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aeglea BioTherapeutics logo
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $0.32
Low: $0.32
High: $0.35

50 Day Range

MA: $0.45
Low: $0.30
High: $0.61

52 Week Range

Now: $0.32
Low: $0.30
High: $3.17

Volume

52,801 shs

Average Volume

320,209 shs

Market Capitalization

$21.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Aeglea BioTherapeutics?

The following sell-side analysts have issued reports on Aeglea BioTherapeutics in the last year: HC Wainwright, Jonestrading, Needham & Company LLC, Piper Sandler, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for AGLE.

What is the current price target for Aeglea BioTherapeutics?

4 Wall Street analysts have set twelve-month price targets for Aeglea BioTherapeutics in the last year. Their average twelve-month price target is $1.88, suggesting a possible upside of 482.7%. Jonestrading has the highest price target set, predicting AGLE will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.00 for Aeglea BioTherapeutics in the next year.
View the latest price targets for AGLE.

What is the current consensus analyst rating for Aeglea BioTherapeutics?

Aeglea BioTherapeutics currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGLE will outperform the market and that investors should add to their positions of Aeglea BioTherapeutics.
View the latest ratings for AGLE.

What other companies compete with Aeglea BioTherapeutics?

Other companies that are similar to Aeglea BioTherapeutics include Zynerba Pharmaceuticals, NightHawk Biosciences, PaxMedica, Equillium and Edesa Biotech. Learn More about companies similar to Aeglea BioTherapeutics.

How do I contact Aeglea BioTherapeutics' investor relations team?

Aeglea BioTherapeutics' physical mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company's listed phone number is (512) 942-2935 and its investor relations email address is [email protected] The official website for Aeglea BioTherapeutics is www.aegleabio.com. Learn More about contacing Aeglea BioTherapeutics investor relations.